3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Colorectal Neoplasms
260
Carcinoma, Non-Small-Cell Lung
125
Glioblastoma
105
Breast Neoplasms
104
Ovarian Neoplasms
96
Carcinoma, Hepatocellular
88
Brain Neoplasms
71
Rectal Neoplasms
69
Neoplasm Metastasis
69
Lung Neoplasms
65
Colonic Neoplasms
58
Neoplasms
57
Glioma
52
Fallopian Tube Neoplasms
44
Carcinoma, Renal Cell
36
Gliosarcoma
31
Pancreatic Neoplasms
30
Melanoma
27
Liver Neoplasms
26
Stomach Neoplasms
21
Astrocytoma
21
Adenocarcinoma of Lung
21
Recurrence
20
Kidney Neoplasms
19
Colorectal Cancer Metastatic
17
Triple Negative Breast Neoplasms
16
Esophageal Neoplasms
15
Uterine Cervical Neoplasms
14
Sarcoma
13
Prostatic Neoplasms
13
Interventions
pembrolizumab
2
fludarabine
2
Radiosurgery
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
regorafenib
1
pazopanib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
ibrutinib
1
grapiprant
1
fludarabine phosphate
1
famitinib
1
encorafenib
1
copanlisib
1
cemiplimab
1
capivasertib
1
camrelizumab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Disease Progression
×
Bevacizumab
×
Clear all
NCT02761070
2023-03-08
RE-GEND
Kyorin University
Phase 3
Unknown
146 enrolled